Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2009

View Archived Issues

Phase III study adds to evidence for milnacipran in fibromyalgia

Oral parathyroid hormone treatment appears feasible

Four-year COMBAT data show BPH improvement with Duodart

CSIR discloses naphthalimide-benzimidazole hybrids for the treatment of cancer

O2h 10/08 identified as potential candidate for the treatment of AD

Merck & Co claims angiotensin receptor antagonists for the treatment of hypertension

Preclinical evaluation of novel nAChR agonist CP-810123 disclosed by Pfizer

Meloxicam is an effective treatment for refractory nocturia in BPH patients

Pre-liver transplant therapy with PEG/RBV reduces HCV recurrence

Gruenenthal describes B1 receptor antagonists for the treatment of pain

Allergan presents EP2 receptor agonists for the treatment of glaucoma

Nabi Biopharmaceuticals starts phase III trial of NicVAX as an aid to stop smoking

Ironwood and Forest report results of two phase III linaclotide trials in constipation

AFM grants Santhera award for nonclinical trials of omigapil for CMD

Xoma and Kaketsuken sign agreement for antibody research and development

SurModics and NuPathe sign license agreement for drug delivery technology in PD

Adeona starts controlled trial of Zinthionein oral zinc therapy for Alzheimer's disease

Antigenics reports results from third quarter of 2009

Canadian marketing approval for BioMimetic Therapeutics' Augment Bone Graft

Idenix initiates phase II clinical trial of IDX-184 in patients with HCV

FDA and European Commission grant orphan drug status to Zeltia's Nypta for PSP

MediciNova initiates phase Ib clinical trial of MN-221 in moderate to severe COPD

PAION reports results from phase IIa trial of CNS-7056 in upper GI endoscopy

Tolera Therapeutics files IND with FDA for TOL-101 to prevent organ transplant rejection

GSK continues enrollment in phase III trial of malaria vaccine with QS-21adjuvant

BioCryst's partner Shionogi files NDA for peramivir in Japan

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...